Morgan Stanley analyst Terence Flynn maintains Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $1023 price target.
Morgan Stanley Maintains Overweight on Eli Lilly and Co, Maintains $1023 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.